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months. RESULTS: 137 patients were enrolled (median age =
28.3 years, from 2.7 to 48.5 years, 49.6% male). At enrolment
112 (81.7%) patients had at least one thalassemia related com-
plication (42.3% had hepatic, 58.4% endocrine, 18.2% cardiac
diseases, 55.5% viral infections). Patients treated with DFO were
51.5%, 31.6% were treated with L1, 16.9% with DFO + L1.
Treatment in patients taking DFO cost on average
€552.88/patient/month plus €211.20 for pump and consum-
ables; patients taking L1 cost €383.25/patient/month, patients
taking DFO + L1 cost €918.41. Overall, mean direct cost was
€1245.33/patient/month, with ICT representing 55.4% of costs,
followed by transfusions (33.1%), hospitalizations and surgery
(3.3%), laboratory and instrumental tests and medical visits
(3.1%), concomitant medications (1.6%), non-medical costs
(transportation, 3.4%). CONCLUSION: Transfusion and ICT
account for 90% of total costs, corresponding to approximately
€1000/patient/month. These results can be considered conserva-
tive because some sources of costs (e.g. nursing, home care) were
not estimated, anyway we do not expect the amount of not
included costs would signiﬁcantly affect our results.
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People with hematological disorders such as beta thallasemia
major (TM) who regularly receive blood transfusions need iron
chelation therapy (ICT) to prevent iron overload. The drugs most
frequently given are deferoxamine and deferiprone. So far, little
is known about the costs related to iron chelation treatment.
OBJECTIVE: To receive information about indirect costs due to
ICT. METHODS: The Italian-THAlassemia-Cost-&-Outcomes-
Assessment (ITHACA) is a naturalistic, multicenter, retrospec-
tive study involving patients with TM of any age, on ICT for at
least 3 years, sequentially enrolled at 8 Italian Thalassemia Care
Centers. Indirect costs were estimated with modiﬁed versions of
the “Health and Labour Questionnaire” (HLQ). RESULTS: A
total of 116 Italian TM patients completed the HLQ. Sixty-one
patients (52.7%) were in paid employment. 21 (34.4%) had
experienced absenteeism from work due to ill health in the pre-
vious 2 weeks. The average absenteeism among patients in paid
employment was 0.7 days/week. Indirect costs related to absen-
teeism are 27.55 euros per patient a week (based on net earn-
ings). Fifteen patients (26.4% of patients in paid employment)
were hindered by health problems at work. Indirect costs per
patient based on hours needed to catch up on tasks neglected
due to health problems were 9.5 euros/week. Patients in our
study received 1.24 hours of household help/week, adding up to
64.74 hours per patient a year. No differences were detected in
the above between patients using deferoxamine, deferiprone or
a combination of both, possibly due to the limited sample size.
21 children (or their caregivers) completed the “HLQ children-
part” (average age 10.7). In the previous twelve weeks 18 chil-
dren missed schooldays (mean = 0.64 days/week) and 6 children
missed regular activities. CONCLUSIONS: TM and current
treatment strategies have a high impact on patients’ productiv-
ity leading to considerable costs. Children with TM miss school-
days on a regular basis.
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OBJECTIVE: To assess by a modeling example under which con-
ditions a combination of adult population genetic screening 
programs is cost-effective. METHODS: Based on a systematic lit-
erature review, hereditary haemochromatosis (HFE) was selected
as a potentially cost-effective primary DNA screening target. 
A secondary condition where population screening exhibits
favourable effectiveness yet unfavourable cost-effectiveness is
hereditary nonpolyposis colorectal cancer (HNPCC). A decision
tree for DNA screening for selected mutations in adult male Cau-
casians was constructed from a health care sector perspective for
HFE, HNPCC, both combined and all three alternatives includ-
ing ﬁrst-degree relatives. Cost data from a recent HFE screening
cost study in Germany were applied; HNPCC mutation preva-
lences were estimated based on data from the German HNPCC
consortium. RESULTS: The model renders a cost-effectiveness
ratio of approximately 100.000 Euro per life-year gained for the
dominated HNPCC screening option, 300 EUR/LYG for HFE
screening and 600 EUR/LYG for combined screening. Cost-effec-
tiveness is most sensitive to different values for HFE penetrance
and cost of genetic counselling found in the literature. Despite
high incremental cost-effectiveness ratios for single HNPCC
mutations added, the average cost-effectiveness ratio of the DNA
test remains moderate if high test speciﬁcity is assured. Effec-
tiveness and cost-effectiveness improve substancially if ﬁrst-
degree relatives are included. CONCLUSIONS: Rather than
disease predisposition screening for frequent single nucleotid
polymorphisms (SNPs) with low penetrance, it appears worth-
wile to screen for rare mutations with high penetrance, combined
with screening for HFE. Product developers in the in-vitro diag-
nostics industry may follow this approach to design cost-effec-
tive screening tools like DNA chips. The screening algorithm
should be designed in a way to minimize the number of false-
posities. Pre-test counselling should identify cases of familial
cancer and ensure that negative test results are not misinterpreted
as private mutations cannot be identiﬁed by a test for known
HNPCC mutations.
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OBJECTIVES: Patients with β-Thalassemia Major (MT) require
life-long blood transfusions, which often cause iron overload
that may increase patients’ morbidity and mortality. Iron 
Chelation Treatment (ICT), based on 8–12 hour infusions of
Deferoxamine for 5–7 days/week, and/or Deferiprone orally
administered, is aimed to reduce iron overload but can be related
to low satisfaction, low compliance and potentially negative con-
sequences on clinical effectiveness and patients’ wellbeing Aims:
to investigate on Health-Related Quality-of-Life (HRQoL) of
MT patients under ICT. METHODS: The Italian-THAlassemia-
Cosy-&-Outcomes-Assessment (ITHACA) was a naturalistic
multicentre study conducted to evaluate costs, HRQoL, compli-
ance and treatment satisfaction in MT patients undergoing ICT.
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Patients with MT of any age, on ICT for at least three years,
were sequentially enrolled at eight Italian Thalassemia Care
Centers. HRQoL was measured in >14 year-old, patients, who
completed 2 generic instruments, EQ-5D and Short Form-36 (SF-
36). RESULTS: Results refer to 121 patients, with median age =
29.8 (14.1–48.5), 49.6% male. At enrolment 87.6% of patients
had at least one thalassemia related complication, 48.3% were
treated with Deferoxamine, 32.5% treated with Deferiprone,
19.2% were treated with both; 14.0% changed treatment
regimen at least once during the observational period (11.6
median months). EQ-5D proﬁle patients reported moderate
problems with “mobility” (9.1%), “self care” (0.8%), “usual
activities” (23.5%), moderate or severe “pain/discomfort”
(60.5%) and “anxiety/depression” (39.5%). The EQ-Visual
Analogue Scale had a mean = 73.0 (median = 75.0, from 30 to
100). Similar trends were observed with the SF-36 ones: in par-
ticular the mean + SD Physical Component Summary score was
47.7 + 8.4; the mean + SD Mental Component Summary score
was 45.1 + 8.8. CONCLUSIONS: Thalassemic patients have
impaired levels HRQoL: both physical and mental components
seem to be compromised from the disease or ICT and related
consequences. Therapies improving patients’ satisfaction with
and compliance to ICT may have positive consequences not only
on clinical effectiveness but also on overall patient’s wellbeing.
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OBJECTIVES: Patients with thalassemia, sickle cell disease
(SCD), and myelodysplastic syndromes (MDS) require infusion
iron chelation therapy (ICT) involving 8–12 hour infusions, 5
days per week, potentially limiting quality of life (QoL) and
inhibiting adherence in patients already limited by their condi-
tion. Thus, satisfaction with ICT is an important treatment
outcome. To date, there is no well-established measure to quan-
tify patient satisfaction with ICT. The aim of this study is to
describe the development and scoring of a treatment satisfaction
instrument for patients taking ICT. METHODS: Based on a lit-
erature review, and patient and clinician interviews, a 28-item
instrument was developed as funded by Novartis. This included
an assessment of: satisfaction with prior experience with ICT;
satisfaction with ICT characteristics; adherence to treatment;
preferences; and behavioural intentions. U.S. and U.K. patients
with thalassemia, SCD, or MDS (n = 110) currently taking ICT
completed the satisfaction instrument. The scoring of the instru-
ment and the assessment of its reliability and validity was per-
formed on the 19 satisfaction items. The 9 items related to past
experience, intentions and preferences were scored separately.
RESULTS: The Principal Component Analysis using a varimax
rotation revealed a four dimensional structure that explained
63% of the total variance. The factors of the Satisfaction with
ICT instrument were labelled: Perceived Effectiveness of ICT (6
items); Burden of ICT (5 items); Acceptance of ICT (5 items);
and Side-effects of ICT (3 items). Internal consistency reliability
for all subscales was good, with alpha coefﬁcients ranging
between 0.80 for Acceptance of ICT to 0.86 for Perceived Effec-
tiveness. CONCLUSIONS: Preliminary analyses suggest that the
Satisfaction with ICT instrument is reliable. Further validation
of the instrument is required to assess its test-retest reliability,
construct validity and responsiveness. The instrument could be
used in routine clinical practice or in clinical trials to measure
satisfaction with ICT.
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OBJECTIVE: Treatment for hemophilia patients with inhibitors
is costly and challenging for its complexity, without clear agree-
ment on drug selection or optimal dosing regimen for the ﬁrst-
line management of bleeding episodes. This study sought to
identify treatment attributes that are important to hematologists
in the United States. METHODS: A conjoint analysis was con-
ducted to elicit preferences using a discrete choice experiment.
Twelve attributes were assessed: risk of human viral infections,
possibility that the titer of the inhibitor may rise, reduction 
in the likelihood of dose-related thromboembolic events, the
number of infusions required to stop hemorrhage, infusion
preparation time, infusion time, infusion volume, time required
to stop bleeding, time required to alleviate pain, prophylaxis use,
ability to undergo major surgery, and cost of medications. Thirty
hematologists completed questionnaires involving twelve choice
tasks with trade-offs between three scenarios (most likely to use,
no preference, and least likely to use). Data were analyzed using
a multinomial logit model to obtain relative importance of each
attribute. RESULTS: Responding hematologists (with an average
of 13 years of experience treating hemophilia patients with
inhibitors) treat on average a total of 28 patients including four
inhibitor patients per month. “Time required to stop bleeding”
was the most important factor affecting treatment decisions (rel-
ative importance (RI) = 16.3%). Physicians also preferred treat-
ment products that possessed quick pain relief (RI = 12.9%), no
possibility that the titer of inhibitor may rise (RI = 12.8%), fewer
number of infusions required to stop a hemorrhage (RI =
12.7%), and absence of risk of human viral infection (RI =
10.8%). CONCLUSIONS: The study revealed the most impor-
tant attributes of treatment for hemophilia patients with
inhibitors from the physician perspective. Future studies should
compare physician preferences with those of hemophilia patients
with inhibitors.
PHM13
SATISFACTION WITH IRON CHELATION THERAPY AND ITS
IMPACT ON ADHERENCE IN PATIENTS WITH BETA
THALASSEMIA MAJOR: RESULTS FROM THE ITHACA STUDY
Rofail D1, Ravera S2, Scalone L3, Cappellini M4, Mantovani LG5
1Mapi Values Limited, Macclesﬁeld, UK, 2Center of
Pharmacoeconomics, University of Milan, Milan, Italy, 3University of
Milan, Milan, Italy, 4Congenital Anemia Center, IRCSS Foundation
Policlinico, Mangiagalli, Regina Elena Hospitals and University of Milan,
Milan, Italy, 5University of Naples, Federico II, Naples, Italy
Patients with β-Thalassemia Major (MT) require life-long blood
transfusions, which often cause iron overload that, if left
untreated, may increase patients’ morbidity and mortality. Iron
Chelation Treatment (ICT), is based on 8–12 hour infusions of
Deferoxamine for 5–7 days/week and/or Deferiprone orally
administered. ICT aims to reduce iron overload but low satis-
faction and low compliance, lead to potentially negative conse-
quences on treatment effectiveness. OBJECTIVES: To investigate
ICT satisfaction in MT patients and explore its relationship with
their thinking about stopping medication. METHODS: The
